Copyright: ©Author(s) 2026.
World J Gastrointest Surg. Jun 27, 2026; 18(6): 119272
Published online Jun 27, 2026. doi: 10.4240/wjgs.119272
Published online Jun 27, 2026. doi: 10.4240/wjgs.119272
Table 4 Overview of treatment-related adverse event, n (%)
| 0 | 1-2 | 3-4 | |
| Hypertensive | 65 (73.80) | 23 (26.13) | 0 (0.00) |
| ALT/AST elevated | 60 (68.18) | 25 (28.41) | 3 (3.41) |
| Leukopenia | 86 (97.73) | 2 (2.27) | 0 (0.00) |
| Thrombocytopenia | 84 (95.45) | 3 (3.41) | 1 (1.14) |
| Neutropenia | 86 (97.73) | 2 (2.27) | 0 (0.00) |
| Anemic | 86 (97.73) | 2 (2.27) | 0 (0.00) |
| Elevated creatinine | 85 (96.59) | 3 (3.41) | 0 (0.00) |
| TSH elevated | 84 (95.45) | 4 (4.55) | 0 (0.00) |
| Vomiting | 86 (97.73) | 2 (2.27) | 0 (0.00) |
| Constipation | 68 (77.27) | 20 (22.73) | 0 (0.00) |
| Anorexia | 84 (95.45) | 4 (4.55) | 0 (0.00) |
| Dermatitis or rash | 66 (75.00) | 22 (25.00) | 0 (0.00) |
| Fatigue | 85 (96.59) | 3 (3.41) | 0 (0.00) |
- Citation: Li QS, Hu AY, Chen SJ, Yu GJ, Fan Y, Chen YG, Tian S, Peng CJ, Han M. Efficacy and safety of adjuvant targeted immunotherapy for hepatocellular carcinoma with high recurrence risks after hepatectomy. World J Gastrointest Surg 2026; 18(6): 119272
- URL: https://www.wjgnet.com/1948-9366/full/v18/i6/119272.htm
- DOI: https://dx.doi.org/10.4240/wjgs.119272